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ViabilityNumerous studies have reported associations between IGF-I and other extra cellular matrix (ECM) proteins, in-
cluding ﬁbronectin (FN), integrins, IGF-binding proteins (IGFBPs) and through IGFBPs, with vitronectin (VN).
Nevertheless, the precise nature and mechanisms of these interactions are still being characterised. In this
paper, we discuss transglutaminases (TGases) as a constituent of the ECM and provide evidence for the ﬁrst
time that IGF-I is a lysine (K)-donor substrate to TGases. When IGF-I was incubated with an alpha-2 plasmin
inhibitor-derived Q peptide in the presence of tissue transglutaminase (TG2), an IGF-I:Q peptide cross-linked
species was detected using Western immunoblotting and conﬁrmed by mass spectrometry. Similar ﬁndings
were observed in the presence of Factor XIIIa (FXIIIa) TGase. To identify the precise location of this K-donor
TGase site/s on IGF-I, all the three IGF-I K-sites, individually and collectively (K27, K65 andK68),were substituted
to arginine (R) using site-directed mutagenesis. Incubation of these K→R IGF-I analogues with Q peptide in the
presence of TG2 or FXIIIa resulted in the absence of cross-linking in IGF-I analogues bearing arginine substitution
at site 68. This established that K68 within the IGF-I D-domain was the principal K-donor site to TGases. We fur-
ther annotated the functional signiﬁcance of these K→R IGF-I analogues on IGF-I mediated actions. IGF-I ana-
logues with K→R substitution within the D-domain at K65 and K68 hindered migration of MCF-7 breast
carcinoma cells and correspondingly reduced PI3-K/AKT activation. Therefore, this study also provides ﬁrst in-
sights into a possible functional role of the previously uncharacterised IGF-I D-domain.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Insulin-like growth factor-I (IGF-I) is structurally similar to insulin
and is part of a complex system including six high afﬁnity IGF binding
proteins (IGFBPs) and two membrane bound IGF receptors [1,2]. IGF-I
mediates the majority of its cellular effects by signal transduction
through the type-1 IGF receptor (IGF-1R). Changes in the delicate bal-
ance of the tightly regulated IGF-I signalling axis have been shown to
be capable of triggering a cascade ofmolecular events that lead to growth
and developmental defects, aberrant wound healing and in some cases,
malignancy [2–4]. Mature IGF-I protein consists of four domains named
BCAD (in order from N- to C-terminus), whilst the precursor IGF-I pro-
tein also has an E peptide at the C terminus. Residues in B and A domains
of IGF-I have been demonstrated to be involved in the binding of IGFBPs-cellular matrix; RTK, receptor
; TG2, tissue transglutaminase;
bronectin; IGFBPs, IGF binding
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ights reserved.[5,6], whereas critical residues in domains B, C and A are involved in re-
ceptor binding and activation [7–9]. Despite signiﬁcant efforts, the func-
tional importance of the ﬂexible C-terminal D-domain of IGF-I has not
been elucidated [10]. However, the D-domain is highly conserved across
species, indicating that it potentially has an important role inmodulating
the various actions of IGF-I. Nevertheless, its removal does not reduce
receptor binding [11] and it is the only domain to remain exposed to an-
tibodies when bound to IGF-1R or IGFBPs [10]. Interestingly enough, the
D-domain of IGF-I (containing two of IGF's three lysine residues) shows
high homology to a consensus peptide sequence of lysine-donor sub-
strates of transglutaminases (TGases) identiﬁed by Grootjans et al. [12].
This suggests that the D-domain residues of IGF-I may act as substrates
to these cross-linking TGase enzymes.
TGases are a family of structurally and functionally related enzymes
that catalyse the formation of isopeptide bonds by transamidation of
available glutamine residues in a range of different proteins [13–16].
TGases are intimately involved in the body's response to wounding, as
evident from their frequent up-regulation during the wound healing
process. Tissue transglutaminase (TG2) is a ubiquitous member of the
TGase family and has been reported in numerous studies as being ame-
diator of the wound healing process [17,18]. Factor Thirteen (FXIIIa),
another TGase widely known for its role in stabilising blood clots, is re-
sponsible for cross-linking ﬁbrin monomers during haemostasis as an
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Werner [21] describes cancer as an over healing wound by drawing
parallels between the commonly shared cellular processes and compar-
ing similarities of wound granulation tissue with tumour stroma. And
the major difference only is the migratory or invasiveness of the
transformed epithelial cells within the tumour. Members of the IGF-I
signalling axis as well as TG2 are implicated in the pathogenesis of
many different cancers, including breast [22,23], prostate [24], lung
[25], ovarian [26] and colon cancer [27]. In addition, TG2 expression
levels also demonstrate a positive correlation between chemotherapy
resistance and metastatic potential by exerting an anti-apoptotic effect
on cancer cells [28,29]. This has been shown to occur through constitu-
tive activation of cell survival and proliferation pathways such as the
phosphatidylinositide 3-kinase (PI3-K) and the mitogen-activated pro-
tein kinase (MAPK) pathways, each of which is stimulated by IGF-I sig-
nalling [28,30–34]. TGases have been increasingly investigated for their
role in protein cross-linking, with several new substrates for these en-
zymes identiﬁed. Several of these substrates have been shown to be
present in the extracellularmatrix (ECM) surrounding cells; ﬁbronectin
(FN), vitronectin (VN), several collagens, laminin–nidogen complexes
and osteopontin are the ECM proteins that are cross-linked by TGases
[reviewed in 30]. Concomitantly, TGases have also been shown to inte-
grate with receptors of these ECM proteins (integrins) [35,36]. Interest-
ingly, some IGFBPs, known to be present in the ECM, have been
established as substrates for TGases such as IGFBP-1 [37] and IGFBP-3
[38].
Our laboratory has previously established that IGF-I, IGFBPs and VN
formmulti-protein complexes that enhance the attachment, proliferative
and migratory ability of normal as well as malignant epithelial cells
[39,40]. These effects have been shown to be mediated via co-activation
of the IGF-1R and VN (and TGase)-binding αvβ3 and αvβ5 integrins
[41]. Since the majority of these proteins in the treatment have been in-
dependently shown to be cross-linked by TGases, we considered the pos-
sibility that TGases may form an integral part of such a complex. Hence,
we investigated and herein present evidence that IGF-I is a substrate for
TGases. Additionally,we further report the involvement of lysine residues
of IGF-I in modulating downstream cellular functions.
2. Methods
2.1. Cell culture
The MCF-7 human breast carcinoma cell line (Cat no. HTB-22)
obtained from the American Type Culture Collection (ATCC, Manassas,
VA) were maintained at 37 °C, 5% CO2 in Dulbecco's Modiﬁed Eagle's
Medium/Ham's F12 (DMEM/F12) medium (1:1) (Life Technologies)
containing 15 mM HEPES, 10% FCS (HyClone, VIC, Australia), 1%
penicillin + streptomycin (Life Technologies) and 0.01% gentamicin
(Life Technologies). The identity of theMCF-7 cell line was authenticat-
ed using short-tandem repeat (STR) proﬁling (CellBank Australia).
Spodoptera frugiperda-derived Sf9 cells (Life Technologies) were cul-
tured in Sf900-II serum free medium (Life Technologies) containing
1% penicillin + streptomycin and 0.01% gentamicin.
2.1.1. Engineering, expression and puriﬁcation of recombinant IGF-I
analogues
Human IGF-I DNA sequence (NCBI #X03563) was codon-optimised
for expression in S. frugiperda and synthesised by GeneArt (Regensburg,
Germany). The coding sequences were cloned into the pIB/V5-His ex-
pression vector (Life Technologies) according to protocols described
by Van Lonkhyuzen et al. [42]. For nucleotide and amino acid sequences
of the IGF-I insert, refer to Supplementary Fig. 1. The K→R IGF-I ana-
logues were produced by performing either site-directed mutagenesis
PCR or restriction digestion/ligation of the generated pIB/wtIGF-I vector.
Four of the seven K→R IGF-I analogues: R27-, R65-, R68- and R65/
R68-IGF-Iwere produced by site-directedmutagenesis PCR as describedin [42]. For sense and antisense primer sequences refer to Supplementa-
ry Table 1. IGF-I analogues obtained using site-directed mutagenesis
were used to create the remaining constructs (R27/65-, R27/68- and
R27/65/68-IGF-I) through restriction digestion and subsequent ligation.
Restriction enzymes ScaI and BspMI (New England Biolabs, MA, USA)
were used to digest in between the R27 and R65/R68 sites. Vector seg-
ments containing the required arginine sites were then gel puriﬁed
(Qiagen gel extraction kit) and ligated (T4 DNA ligase; New England
Biolabs) to produce the resultant vectors. Their DNA sequences were
veriﬁed at the Australia Genome Research Facility (AGRF), Brisbane,
Australia.
Sequence-veriﬁed pIB/IGF-I vectors were transfected into log-phase
Sf9 insect cells and the expressed IGF-I protein was detected in the
conditioned media through immunoblotting using anti-IGF-I anti-
body. Puriﬁcation of the recombinant IGF-I analogues was based on
Ni2+-NTA Superﬂow agarose (Qiagen) afﬁnity chromatography
performed according tomanufacturer's instructions (Supplementary
Method 1). Eluted fractions tested for IGF-I immunoreactive species
were evaporated to dryness, and resuspended in 200 μL of 10 mM
acetic acid. The concentrations of these puriﬁed IGF-I analogues
were determined using routine Coomassie staining (Sigma-Aldrich)
and Bradford assay (Pierce) following manufacturer's instructions
and stored at−80 °C until further use.
2.2. Cross-linking of rIGF-I to Q peptide in the presence of TGases
Q peptide was a biotinylated peptide (NQEQVSPLK-biotin, mass
1267 Da) generated from the TGase substrate sequence of alpha-2
plasmin inhibitor (GL Biochem Ltd., Shanghai, China). The expressed
IGF-I analogues and rIGF-I were incubated with ﬁvefold molar excess
of Q peptide in the presence of 0.75 units of FXIIIa or TG2. These
reactions were incubated at 37 °C for 30 min in 10 μL reaction volumes
in the presence of 2.5 mM CaCl2 and 50 mM tris–HCl (pH adjusted to
8.0 at room temperature). One half of the reaction was analysed
using SDS-PAGE and Western immunoblotting. The remainder was
evaporated to dryness, resuspended in 2% formic acid and analysed
using liquid chromatography–electrospray ionisation-mass spectrome-
try (LC–ESI-MS).
2.3. Mass spectrometry
2.3.1.Whole protein analysis via liquid chromatographymass spectrometry
(LC–MS)
LC–MS was performed using a Shimadzu Prominence nano-HPLC
interfaced with an AB SCIEX Q STAR Elite system, ﬁtted with a
nanospray ion source and running Analyst QS 2.0. Protein samples
(10 μL; 0.2 μg protein in 2% formic acid) were injected onto a
150 mm × 75 μm C18 column (Vydac) and separated on a two-step
gradient at a constant ﬂow of 300 nL/min (0.9–54% AcN, 11 min; 54–
72% AcN, 4 min) in the presence of 0.1% formic acid. Full scan time-of-
ﬂight (ToF)-MS data was obtained over the mass range of 500–2000.
The molecular weight of the proteins was calculated using Bayesian re-
construction, as implemented in Analyst QS.
2.3.2. In gel digestion and liquid chromatography–tandem mass
spectrometry (LC–MS/MS) analysis
Following SDS-PAGE and Coomassie staining, selected gel plugs
were excised using sterile scalpels and subjected to overnight digestion
using chymotrypsin (Roche Diagnostics; Castle Hill, NSW, Australia).
Refer Supplementary Method 2 for further details. Digested peptides
(5 μL) were subjected to LC–MS/MS, where the samples were injected
onto a 50 mm × 300 μm C18 trap column (Agilent) at 20 μL per min
and separated on a 150 mm × 75 μm C18 column (Vydac; 300 nL/min,
0.1% formic acid; 0.9–32% AcN, 50 min; 32–72% AcN, 10 min). Full scan
ToF-MS data was acquired over the mass range of 350–1800 and for
product ion ms/ms of 100–1800. Collision-induced dissociation (CID)
Fig. 1. IGF-I is a substrate to FXIIIa and TG2. Cross-linking of rIGF-I to Q peptide was
performed at 37 °C for 30 min in the presence of 0.75 units of FXIIIa and TG2, respectively
(lanes as indicated). The reaction products were analysed on 4–12% bis–tris PAGE gels
followed by immunoblotting using anti-IGF-I antibody. The cross-linking reaction is con-
ﬁrmed by the presence of a higher molecular weight of ~1 kDa above rIGF-I.
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alytical data ﬁles were searched for peptides corresponding to IGF-I and
Q peptide on the ProteinPilot Software (AB SCIEX, Foster City, CA) using
the Paragon Algorithm.
2.4. BIAcore — surface plasmon resonance (SPR)
The binding kinetics of each IGF-I analogue to IGFBP-3 was assessed
by SPR using the BIAcore X100 system (GE Healthcare). IGFBP-3 was
biotinylated using an EZ-Link Sulfo-NHS-LC-Biotin kit at 1:1 M ratio fol-
lowing the manufacturer's instructions (Pierce). HBS-EP + buffer
(0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Surfactant P20,
pH 7.4) was used throughout as the running buffer and as the diluent
for all reagents. The biotin capture reagent (CAP) was immobilised to
the CAP sensor chip by injection at 5 μL/min for a contact time of
300 s. Biotinylated IGFBP-3 was then injected onto the surface of the
CAP sensor chip at 5 μL per min until approximately 100 response
units (RU) were immobilised in each experiment. A reference ﬂow cell
with only CAP reagent immobilisedwas used as a binding control. A sin-
gle cycle kinetics method was employed at a rate of 30 μL/min; where
each concentration (0.03 nM, 0.11 nM, 0.33 nM, 1 nM, 3 nM) was se-
quentially injected and separated by association and dissociation pe-
riods of 120 s, followed by a ﬁnal dissociation period of 600 s. Kinetic
analysis was performed using the 1:1 binding model on the reference
subtracted sensorgrams [43].
2.5. Treatment approach for in vitro studies investigating IGF-I
(recombinant and expressed analogues) on cell function
We adopted the previously employed substrate-bound IGF-I:IGFBP:
VNmultimeric complex approach to investigate the role of the TG lysine
residues of IGF-I in stimulating cell proliferation andmigration. This ap-
proach was adopted to more accurately mimic the in vivo cellular envi-
ronment in which cells are not constantly exposed to growth factors in
solution, but rather, interact with growth factors associated with com-
ponents of the ECM [41,44,45].
2.6. Pre-binding cultureware with proteins
In all the functional assays prior to cell seeding native/K→R IGF-I
(13 nM), IGFBP-3 (11 nM) and VN (13 nM) were pre-bound to the
cultureware, including Transwells following procedures previously de-
scribed [39,41,44,46].
2.7. Cell viability assay
Log phase MCF-7 cells were serum-starved for 4 h and harvested
using cell dissociation buffer (TrypLE™ Express; Life Technologies).
Subsequently, 5 × 103 cells suspended in 100 μL SFM + 0.05% BSA
were seeded into 96-well plates pre-coated with VN alone or in combi-
nation with IGF-I analogues and IGFBP-3. The cells were incubated for
72 h at 37 °C in 5% CO2 and cellular viability was assessed using the
CellTitre 96® AQueous One Solution Cell Proliferation Assay (MTS)
(Promega) as per manufacturer's instructions [47].
2.8. Cell migration assay
Migration assays were performed as described previously [41,44].
Brieﬂy, subconﬂuent MCF-7 cells were serum-starved for 4 h and
2 × 105 cells suspended in SFM + 0.05% BSA were seeded onto the
upper-surface of 8-μm pore Transwell® inserts pre-coated on the
under-surface with VN, either alone or in combination with IGF-I ana-
logues and IGFBP-3. After 14 h migrated cells were ﬁxed using 3.7%
para-formaldehyde and stained with 0.01% crystal violet. The stain
was extracted using 10% acetic acid and absorbance was measured at
595 nm using a plate reader.2.9. Cell signalling and Western immunoblotting
All protein samples, including total proteins extracted from cell
lysates collected from the cell signalling experiments (as performed fol-
lowing previously published protocols [41,44]) were resolved on
NuPAGE® gradient SDS-PAGE gels (4%–12%) (Life Technologies) and
transferred onto polyvinylidene ﬂuoride (PVDF) membranes (Pall Cor-
poration). The membranes were probed with anti-IGF-I (1:5000),
anti-phospho ERK1/2 (1:1000), anti-phospho AKT (1:1000), anti-
phospho IGF-1Rβ (1:1000) antibodies. The membranes were subse-
quently incubated with HRP-linked secondary antibody (1:5000) and
developed using an automated chemiluminescence detector (Molecular
Imager®; Bio-Rad). Themembranes were stripped using Restore™ Plus
stripping buffer (Pierce; Scoresby, VIC, Australia) and the total protein
levels were validated for equal loading using the respective anti-ERK1/
2, anti-AKT or anti-IGF-1R antibodies. Densitometry on the bands was
performed using the ImageLab software (Bio-Rad).
2.10. Statistical analysis
Data were pooled frommultiple experiments as indicated in the ﬁg-
ure legends, with each treatment tested in at least triplicate wells. Data
analysis was performed using ANOVAwith Tukey's post hoc test where
appropriate. Statistically signiﬁcant differences were considered to be
present at p b 0.01.
3. Results
3.1. IGF-I cross-links to glutamine substrate in the presence of TGases
To identify whether IGF-I is a lysine substrate to TGases, rIGF-I was
incubated with a glutamine substrate peptide modelled from the N-
terminus of alpha-2 plasmin inhibitor (Q peptide) [48] in the presence
of FXIIIa and TG2. The cross-linking reaction was run on an SDS-PAGE
gel and immunoblotted for IGF-I. When probed with anti-IGF-I anti-
body, cross-linking of native IGF-I to Q peptide in the presence of FXIIIa
or TG2 was clearly visible as a band of ~1 kDa molecular weight higher
than the rIGF-I only control (Fig. 1). This demonstrated for the ﬁrst time
that IGF-I is a lysine donor substrate to TGases.
3.2. Expression and puriﬁcation of His-tagged IGF-I constructs
In order to both locate and investigate the importance of the TGase
lysine substrate residues within IGF-I, site-directed mutagenesis was
performed to create IGF-I analogues with all possible combinations of
K→R substitution at the three IGF-I lysine sites (K27, K65 and K68).
Western immunoblots of conditioned media from stably transfected
Sf9 cultures revealed the presence of immunoreactive IGF-I species
(Fig. 2), which was at a slightly higher molecular weight compared to
Fig. 2. Expression and puriﬁcation of expressed IGF-I analogues. Expression of native and
K→R IGF-I analogues (labelled as appropriate) was conﬁrmed by analysing 10–20 μL of
conditioned media run on 4–12% bis–tris PAGE gel followed by immunoblotting using
anti-IGF-I antibody. Ten microliters of conditioned media frommock transfection control
was used as negative control (Neg).
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for puriﬁcation of the recombinant analogues.
The eight recombinant IGF-I analogues created (1x wt, 3x single, 3x
double and 1x triple) were then successfully puriﬁed from the condi-
tioned media using the Ni2+-NTA agarose and reversed phase C4 chro-
matography as described in methods (Section 2.1.1). The concentrations
of these puriﬁed IGF-I analogueswere determined using routine Bradford
assay. These concentrations were conﬁrmed by Coomassie staining the
puriﬁed IGF-I analogues (50 ng) in comparison to rIGF-I at 50 ng and
100 ng (Supplementary Fig. 2A). In addition, silver staining of threefold
dilutions (starting from 100 ng) of puriﬁed analogues was performed
against identical dilutions of rIGF-I (Supplementary Fig. 2B).
3.3. Expression veriﬁcation of recombinant IGF-I analogues by mass
spectrometry
The mass of each expressed protein was veriﬁed using LC–ESI-MS.
The observed masses of the recombinant IGF-I analogues were listed
as ‘Experimental mass’ in Table 1. The theoretical molecular weight of
the respective IGF-I analogues was calculated using the ProtParam pro-
gram on the ExPASy proteomics server (http://au.expasy.org/cgi-bin/
protparam) based on their primary amino acid sequences. Mass spectra
of the wt and R68-IGF-I analogue are shown in Supplementary Fig. 3A
and B, respectively.
The experimentalmasses of all the IGF-I analogues, includingwtIGF-I,
corresponded with their respective theoretical masses (Table 1). The
mass spectra of R65/R68-IGF-I andR27/R65/R68-IGF-I, however, demon-
strated two additional species of high abundance, in addition to their full
length construct (see Supplementary Fig. 4A and B, respectively). These
additional species correlated with truncations of two amino acids (-SA)
or three amino acids (-RSA) from the C terminal ends of their respective
full-length constructs. Nevertheless, all the three species observed with
R65/68- and R27/65/68-IGF-I included the loss of the hypothesisedTable 1
Reconstructed masses of IGF-I constructs from liquid chromatography–electrospray
ionisation-mass spectrometry. Summary of masses of recombinant and expressed IGF-I
analogues was generated from total ion current (TIC) chromatogram obtained after
injecting 0.2 μg of respective IGF-I constructs. The reconstructed experimental masses
were compared with their theoretical masses calculated using their primary amino acid se-
quences. Mass spectra of R65/68-IGF-I and R27/65/68-IGF-I revealed two other species cor-
responding to C-terminal deletion of -SA (mass = 159 Da) and -RSA (mass = 315 Da).
IGF-I constructs Theoretical mass (Da) Experimental mass (Da) ΔMass (Da)
Recombinant 7648.74 7647.41 1.27
Expressedwt 9437.60 9437.25 0.35
R27 9465.61 9465.57 0.04
R65 9465.61 9465.67 0.06
R68 9465.61 9465.54 0.07
R27/65 9493.62 9493.93 0.31
R27/68 9493.62 9494.10 0.52
R65/68 9493.62 9494.11, -159, -315 0.49
R27/65/68 9521.64 9522.13, -159, -315 0.49TGase K68 site, either due to its truncation (in -RSA deletion species)
or arginine substitution (in full length as well as -SA deletion species).
Given the presence of these additional species, the double and triple K
→R analogues were only included in characterisation studies to identify
the speciﬁc IGF-I lysine donor site for TGases and were omitted from
functional assays, such as the cell viability, cell migration and cell signal-
ling studies. However, the single K→R constructs formed part of all stud-
ies included in this manuscript.
3.4. K68 is the sole IGF-I lysine donor site for FXIIIa
To demonstrate the exact lysine substrate site/s of IGF-I to FXIIIa,
K→R IGF-I analogues were cross-linked to Q peptide in the presence
of FXIIIa.Whilst the singular mass of Q peptide is 1267 Da, during the
cross-linking reactions, the Q peptide mass appears to be 1251 Da.
This mass difference of Q peptide is attributed to the loss of –NH3
from the Q peptide's glutamine following cross-linking to the lysine
site/s of IGF-I.
When probed with anti-IGF-I antibody, cross-linking of wtIGF-I to Q
peptide in the presence of FXIIIa was clearly visible as a band of ~1 kDa
molecular weight higher than the rIGF-I only control (Fig. 3A). This was
also observed in the R27-, R65- and R27/R65-IGF-I analogues. However,
all IGF-I analogues bearing R68 showed no shift in their molecular
weight (Fig. 3A). The comprehensive blots of the cross-linking reaction
of each of these IGF-I analogues are individually presented in Supple-
mentary Fig. 5. This suggests that IGF-I analogues containing R68 were
unable to cross-link Q peptide, indicating that K68 is the sole lysine
donor site of IGF-I to FXIIIa.
Presence or absence of cross-linking for each reaction was further
conﬁrmed by LC–ESI-MS, with the appearance of a peak that corre-
sponds to the Q peptide peak of 1251 Da added on to the native IGF-I
peak. For instance, the addition of FXIIIa to wtIGF-I in the presence of
Q peptide resulted in a shift in the mass (from 9437 Da to 10,687 Da)
being observed on the mass spectrum (Fig. 3B), whereas no such shift
inmass was observed for R68-IGF-I (Fig. 3C). For additional information
on the cross-linking of rIGF-I to Q peptide, please refer to Supplementa-
ry Fig. 6.
To further conﬁrm the precise cross-linking sites within IGF-I, the
cross-linked bands (higher molecular weight bands) observed in the
SDS-PAGE gels were excised and digested with chymotrypsin and
analysed by tandem mass spectrometry, LC–MS/MS. These bands were
analysed using the Paragon Algorithm against an in-house database,
which was generated by combining the protein sequence of IGF-I with
that of Q peptide cross-linked at potential IGF-I-binding sites. For exam-
ple, lysines at positions 27, 65 and 68 of rIGF-I are potential sites for Q
peptide binding. Complete peptide coverage of rIGF-I was obtained
from chymotrypsin-cleaved peptides obtained from the gel band corre-
sponding to the control sample ‘rIGF-I only’. Similar peptide coverage
was obtained from higher molecular weight bands seen in the cross-
linking reaction involving rIGF-I and Q peptide. The N-terminal frag-
ment sequence datawas identiﬁed up to the ‘K’ cross-link site. Similarly,
the C-terminal sequence data was identiﬁed up to the ‘Q’cross-link site.
Consequently, a cross-linked peptide at K68 of 1938 Dawas successfully
identiﬁed from the fragmentation data obtained from the mass spec-
trometer. The amino acid sequence of this cross-linked peptide is
depicted in Fig. 4 alongwith their b-ionmasses. Similar resultswere ob-
served from the bands excised from a cross-linking reaction incorporat-
ing wtIGF-I.
Validation of the cross-linking reactionwith R68-IGF-I did not reveal
the presence of a precursor peptide of mass 1938 Da. Analysis of the
cross-linking reaction demonstrated the presence of a single major
peak at 9465 Da corresponding to the R68-IGF-I onlymass. No addition-
al peptide sequence/s corresponding to R68-IGF-I being cross-linked to
Q peptide was observed, suggesting the absence of any alternative
cross-linked products, thus conﬁrming K68 of IGF-I as the primary ly-
sine donor site for FXIIIa. Furthermore, the only other peaks of much
Fig. 3. R68 is the sole IGF-I lysine donor site to FXIIIa. A) Cross-linking of IGF-I constructs to glutamine acceptor substrate, Q peptidewas performed in the presence of 0.75 units of FXIIIa in
20 μL reaction volume at 37 °C for 30 min. All the cross-linking reactionswith expressed IGF-I constructs were comparedwith control reactions containing rIGF-I on 4–12% SDS-PAGE gel.
Western immunoblotting analysis of 10 μL reactionswith anti-IGF-I antibody conﬁrmed cross-linking reaction between IGF-I andQpeptidewith the presence of a highermolecularweight
band as observed in all IGF-I analogues except the ones containing R68. The other 10 μL from the cross-linking reaction was analysed by mass spectrometry. B)Mass spectrum of ‘wtIGF-I
only’ showed a peak at 9437 Da (denoted in black)whilst cross-linking reaction ofwtIGF-I to Q peptidewas demonstrated by amajor peak in themass spectrum at 10,687 Da, an addition
of 1251 Da (Q peptide) to the 9437 Da ‘wtIGF-I only’ peak (denoted in red). C) Mass spectrum of ‘R68-IGF-I only’ showed a major peak at 9465 Da (denoted in black) whilst the mass
spectrum of cross-linking reaction of R68-IGF-I to Q peptide demonstrated an absence of any cross-linked product, since the major peak observed was at 9465 Da (denoted in red)
which corresponded to ‘R68-IGF-I only’ mass.
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peaks representative of multimers of Q peptide, such as peaks atmasses
7606 (6x Q peptide at 1267), 8873 (7x Q peptide at 1267), 10,141 (8x Q
peptide) and 11,409 (9x Q peptide at 1267) (not highlighted in Fig. 3C
for clarity). These peaks were also present and identiﬁed in the cross-
linking reactions with the other IGF-I analogues.3.5. K68 is the principal lysine donor site for TG2
As observed in FXIIIa reactions, cross-linking of native IGF-I to Q pep-
tide in the presence of TG2 was conﬁrmed by the higher molecular
weight cross-linking band present in Western immunoblots probed
with anti-IGF-I antibody (Fig. 5A). This was also observed in all the
other expressed IGF-I analogues except the R27/R65/R68-IGF-I ana-
logue. However, all the IGF-I analogues bearing R68 (R68, R27/R68,
R65/R68) showed reduced cross-linking to Q peptide compared to the
non-R68 analogues. Hence, for TG2, although all the lysine residues of
IGF-I seem to be valid lysine donor sites, K68 is more actively involved
as a TG2 lysine donor than the other two lysine sites. The comprehen-
sive blots of the cross-linking reaction of each of these IGF-I analogues
are individually presented in Supplementary Fig. 7.Fig. 4. Identiﬁcation of crosslinkedpeptide at K68. The cross-linked IGF-I:Q peptide detect-
ed at K68 after digestion by endoprotease chymotrypsin is represented herein. Themasses
of fragment ions (b-ions) observed after LC–MS/MS are also included. A complete cover-
age of peptide is obtained at both N- and C-terminus until the cross-linked portion.A similar shift in mass, as observed in FXIIIa reactions, was also seen
in the mass spectrum of native, R27-, R65- and R27/R65-IGF-I ana-
logues. Signiﬁcant peaks at 10,688 Da and 8898 Da were observed in
themass spectra ofwtIGF-I and rIGF-I, respectively (Fig. 5B and Supple-
mentary Fig. 6C, respectively). Mass spectra of cross-linking reactions
with R68-IGF-I analogue (Fig. 5C) showed the presence of a low inten-
sity peak (200 cps) at 10,715 Da (the expected cross-linking peak).
The cross-linked bands from the silver-stained SDS-PAGE gels were
excised and digestedwith chymotrypsin and analysed using the Paragon
Algorithm against the in-house database. Similar results were observed
as with FXIIIa cross-linking reaction, wherein Q peptide cross-linked
K68-IGF-I was identiﬁed. Although K27 and K65 could also potentially
be involved in the TG2 mediated cross-linking reaction (as suggested
fromWestern immunoblotting results), the secondary site could not be
conﬁrmed through mass spectrometry.
Taken together, studies with TG2 and FXIIIa demonstrate, for the
ﬁrst time, that K68 is a primary lysine donor site within IGF-I.
3.6. Single K→R IGF-I analogues bind to IGFBP-3with a comparable afﬁnity
to native IGF-I
Kinetic properties of the interaction of native IGF-I (rIGF-I andwtIGF-
I) and single K→R IGF-I analogues with IGFBP-3 were assessed using
BIAcore X100 (Fig. 6). A 1:1 Langmuir binding ﬁt model was used to as-
sess the binding afﬁnities of IGF-I analogues for immobilised IGFBP-3.
Both rIGF-I andwtIGF-I showed similar Kd values and hence, were com-
parable and assessed together as ‘native IGF-I’. Compared to native IGF-I,
R27-, R65- and R68-IGF-I showed similar Kd values in their rate con-
stants and binding afﬁnities within the same molar (10−10 M) range
(Table 2). The Kd values for the binding of IGF-I and IGFBP-3 in our stud-
ies were similar to the afﬁnity value of 2.3 ± 0.4 × 10−10 M observed
by Heding et al. [49].
3.7. K→R IGF-I analogues maintain MCF-7 cell viability when presented as
IGF-I:IGFBP-3:VN trimeric complexes
To determine the effects of the IGF-I lysine sites onMCF-7 cell viabil-
ity, we used an approach similar to that described in previous studies
Fig. 5. R68 is the principal IGF-I lysine donor site to TG2. A) Cross-linking of IGF-I constructs to glutamine acceptor substrate, Q peptide, was performed in the presence of 0.75 units of TG2
in 20 μL reaction volume at 37 °C for 30 min. All the cross-linked reactions with expressed IGF-I constructs were compared with control reactions containing rIGF-I resolved on a 4–12%
SDS-PAGE gel. Western immunoblotting analysis of 10 μL reactions with anti-IGF-I antibody conﬁrmed cross-linking of IGF-I to Q peptide by the presence of a higher molecular weight
band. The other 10 μL from the cross-linking reactionwas analysed bymass spectrometry. B)Mass spectrum of ‘wtIGF-I only’ showed a singular peak at 9437 Da (denoted in black)whilst
the cross-linking reaction of wtIGF-I to Q peptide was demonstrated by the major peak in the mass spectrum at 10,688 Da, an addition of 1251 (Q peptide) to 9437 ‘wtIGF-I only’ peak
(denoted in red). C) Mass spectrum of ‘R68-IGF-I only’ showed a major peak at 9465 Da and the cross-linking reaction of R68-IGF-I to Q peptide demonstrated the presence of a major
peak at 9465 Da (denoted in red) corresponding to R68-IGF-I. In addition, a smaller peak at 10,715 Da was also observed which correlates to minimal cross-linking of IGF-I to Q peptide
(denoted in red).
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proach, IGF-I and IGFBP-3 were presented to cells as a complex to
substrate-adsorbed VN, with unbound proteins removed so that cellsFig. 6. Binding curves derived from surface plasmon resonance analysis of IGF-I constructs.
The interaction between IGFBP-3 andwtIGF-I (A), recombinant IGF-I (B) andR68-IGF-I (C)
was determined using single cycle kinetics on a BIAcore X100 system. Binding curves
within the sensorgrams were ﬁtted to a 1:1 Langmuir binding model. Black line in all
three sensorgrams represents the ﬁtted data. Representative sensorgrams from triplicate
experiments are depicted. The biosensorchip response is indicated on the y-axis (ΔRU)
as a function of time (x-axis) at 25 °C.are exposed only to substrate-bound IGF-I. Serum starved MCF-7 cells
were incubated for 72 h in 96-well plates pre-coated with VN, IGFBP-
3 and either native or K→R IGF-I analogues. VN-only treatment was
the negative control whilst the 10% foetal calf serum (FCS) treatment
formed the positive control. IGF-I or IGFBP-3 alone treatments were
not tested as the cells did not adhere to the cultureware in the absence
of VN or serum (data not shown). Metabolic activity within eachwell as
measured by the MTS assay was expressed as a percentage of the VN-
only control (Fig. 7A). Commercially-sourced rIGF-I and the in-house
expressed wtIGF-I both yielded a similar increase in cell viability
above the VN-only control (Fig. 7A). Furthermore, the R27-, R65- and
R68-IGF-I analogues induced cell viability at comparable levels to native
IGF-I (Fig. 7A) and accordingly, all the treatments were signiﬁcantly
greater (p b 0.01) than theVN-only control. These effectswere indistin-
guishable from solution-phase treatments wherein IGF-I and IGFBP-3
were added directly in media to VN-coated wells, with all proteins
added remaining throughout the length of the experiment (data not
shown).
3.8. IGF-I lysine sites within the D-domain of IGF-I signiﬁcantly decrease
IGF-I:IGFBP-3:VN mediated cell migration
The effect of the K→R mutations in IGF-I on MCF-7 cell migration
was examined using the Transwell® migration assay [41,44]. TheTable 2
Native/K→R IGF-I and IGFBP-3 binding kinetics. Binding curve ﬁts for all the IGF-I con-
structs to IGFBP-3 from Fig. 5 were analysed using BIAevaluation software version 2.0.1,
with results tabulated. ka = association rate constant; kd = dissociation rate constant.
KD = dissociation equilibrium constant. The values depicted are means ± SEM obtained
from three independent replicate experiments.
ka × 105 ± S.E.
(s−1 M−1)
ka × 10−4 ± S.E.
(s−1)
ka × 10−10 ± S.E.
(M−1)
rIGF-I 2.55 ± 0.05 5.75 ± 0.18 2.26 ± 0.03
wtIGF-I 2.04 ± 0.10 4.00 ± 0.07 1.98 ± 0.07
R27-IGF-I 1.72 ± 0.11 3.04 ± 0.31 2.49 ± 0.36
R65-IGF-I 1.71 ± 0.27 3.81 ± 0.66 2.38 ± 0.37
R68-IGF-I 0.93 ± 0.12 3.21 ± 0.20 3.68 ± 0.29
Fig. 7. A) Native and expressed IGF-I analogues in IGF-I:IGFBP-3:VN complexes stimulate
cell viability. MCF-7 cell viability in response to native and expressed IGF-I analogues was
assessed over 72 h. The acquired data were pooled from three experiments with treat-
ments tested in at least three wells in each replicate experiment. Asterisks indicate treat-
ments with signiﬁcant increases in percent stimulation compared to the VN-only control
(p b 0.01). 10% FCSwas used as the positive control. Error bars indicate SEM. B) Lysine res-
idues of IGF-I's D-domain enable cell migration. MCF-7 cells were seeded into Transwell
inserts that had the lowerwell and the under-surface of themembrane coatedwith either
native IGF-I or respective single K→R IGF-I analogues in the presence of IGFBP-3 and VN.
The number of cells transversing the membrane in response to each treatment was then
expressed as a percentage of those that migrated on VN-only control. The data are pooled
from three experiments with treatments tested in three wells for each. The asterisk indi-
cates treatments that signiﬁcantly increased migration above the VN-only control
(p b 0.01). Error bars indicate SEM.
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Transwell® inserts were coated with combinations of the respective
IGF-I analogues and IGFBP-3 pre-bound to VN. Cells that had migrated
to the bottom surface after 14 hwere quantiﬁed and expressed as a per-
centage of the VN-only control (Fig. 7B). Migration induced by R27-IGF-
I was not signiﬁcantly different compared to native IGF-I (Fig. 7B), with
the cell migration stimulated by these treatments being signiﬁcantly
greater (p b 0.01) than the VN-only control. However, both R65- and
R68-IGF-I were unable to stimulate migration above that of the VN-Fig. 8. Signiﬁcance of IGF-I lysine sites in IGF-I:IGFBP-3:VN complex-mediated activation of ERK
K→R IGF-I, IGFBP-3 and VN combinations for the indicated times. Cells were then lysed and lev
branes were subsequently stripped and reprobed to determine total levels of IGF-1R, ERK1/2 a
quantiﬁcation data on the band intensities, densitometry was performed on the blots obtained
tein is expressed as fold change of the VN control of each time point. Error bars indicated SEMonly control (Fig. 7B), suggesting that the substitution of these lysine
residues alters the ability of IGF-I to stimulate cell migration. This is
the ﬁrst report demonstrating that the D-domain K65 and K68 residues
within IGF-I are implicated in modulating breast cancer cell migration.
3.9. IGF-1R and AKT activation is reduced in the presence of the R65- and
R68-IGF-I analogues
Previous studies from our laboratory have demonstrated that IGF-I:
IGFBP-3:VN-stimulated cell migration is mediated predominantly
through the PI3-K/AKT pathway downstream of IGF-1R activation,
with little contribution from the ERK/MAPK pathway [41]. Hence, to
investigate if the decreased migration observed in response to the
D-domain K→R IGF-I analogues was accompanied by a concomitant
reduction in IGF-1R and PI3-K/AKT pathway activation, MCF-7 cells
were incubated in wells pre-coated with VN, either alone or in the
presence of IGFBP-3 and with native/K→R IGF-I. The activation (ob-
served through phosphorylation) of IGF-1R, AKT and ERK1/2 was
monitored over 0–3 h via Western immunoblotting, with phosphor-
ylation signals acquired from three independent blots quantiﬁed
using densitometry. The trimeric IGF-I:IGFBP-3:VN complexes con-
taining both the rIGF-I and wtIGF-I induced activation of ERK1/2,
IGF-1R and AKT (up to 3 h) (Fig. 8). This was in accordance with previ-
ously published ﬁndings [41]. Moreover, R27-IGF-I behaved in a manner
similar to native IGF-I, with IGF-1R phosphorylation, AKT and ERK1/2
phosphorylation detected at levels comparable to that of native IGF-I
(Fig. 8 immunoblots as well as densitometry graphs). However, IGF-1R
phosphorylation was substantially reduced in the presence of IGF-I ana-
logues containing K→R in the D-domain (R65-IGF-I and R68-IGF-I) at all
time points tested. Furthermore, the downstream activation of AKT was
also affected in the presence of the R65- and R68-IGF-I, with phosphory-
lation of AKT being comparable to that induced by the VN-only control
(densitometry graphs). Phosphorylation of ERK1/2 was unaffected over
the entire time course across all IGF-I analogues tested (native as well
as K→R). The difference in ERK phosphorylation between VN and the/MAPK and PI3-K/AKT pathways.MCF-7 cells were seeded onwells precoatedwith native/
els of phosphorylated IGF-1R, ERK1/2 and AKT determined by immunoblot analysis. Mem-
nd AKT. Representative blots from three biological replicates are shown. To obtain relative
from the three experiments. The relative intensity for the respective phosphorylated pro-
.
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this data suggests that the K65 and K68 residues present within the
D-domain of IGF-I are critical in initiating the IGF-1R and PI3-K/AKT
pathway activation, thereby potentially inﬂuencing cell migration, the
key functional outcome of the PI3-K/AKT pathway activation.
4. Discussion
The IGF signalling pathway regulates cell proliferation, survival, dif-
ferentiation, and migration via endocrine, paracrine and autocrine
mechanisms. Members of the IGF family are potent mitogens which
have recognised regulatory roles in normal growth and development.
In spite of IGF-I being heavily researched our understanding of all its
functions and the exact nature of its binding interactions with various
proteins remains incomplete. Studies reported herein investigate the
functional signiﬁcance of IGF-I lysine sites and further demonstrate
IGF-I as a lysine donor substrate to the protein cross-linking enzymes
FXIIIa and TG2, through which it can potentially interact with other
known TGase substrates.
4.1. The D-domain of IGF-I contains a TGase lysine substrate site
Several physiological proteins have increasingly been identiﬁed as
TGase substrates. For example, IGFBPs and several other ECM proteins
have been demonstrated to be substrates for TGases including VN, FN
and collagens [reviewed in 30]. Whilst the range of lysine substrate
speciﬁcity for TGases is quite broad, a number of key characteristics
have been identiﬁed. Most TGase lysine substrate sites are found in
the ﬂexible regions of their host protein (loops or more commonly, N-
or C-terminal tails) [10]. Interestingly, this criterion is met by all the
three lysine residues of IGF-I in its free state. In fact, K27 in the IGF-I
C-domain and K65, K68 residues based in the D-domain of IGF-I are ex-
posed to solvent and are highly mobile [50]. However, when IGF-I is
bound to IGFBPs or to the IGF-1R, only the lysine residues in the D-
domain remain exposed. The D-domain is, in fact, the only portion of
IGF-I that remains recognisable by monoclonal antibodies in this state
[10]. Furthermore, the sequence surrounding K68 (PAK68SA) is in
broad agreement with the consensus (P/L)-(S/L/A/R)-K-(OH/L/G/V)
substrate motif for TGases identiﬁed in previous mutagenesis studies
[12,51]. Also, both K65 and K68 have a proline residue in the -2 position,
a feature identiﬁed with all known natural TGase substrates by logistic
regression analysis [52]. Taken together, this suggests that IGF-I
possesses several characteristics of a potential TGase lysine substrate.
Certainly, the data reported in this manuscript indisputably demon-
strates that IGF-I is indeed a lysine donor substrate to FXIIIa and TG2.
Furthermore, analysis of the cross-linking reactions between Q peptide
and K→R IGF-I analogues using Western immunoblotting and mass
spectrometry demonstrates that K68 is the key lysine donor site in
IGF-I to both FXIIIa and TG2. This is a signiﬁcant ﬁnding since TGases
present a vast potential in IGF-I biology as they have been identiﬁed
to interact with integrins as well as other ECM proteins that are well
characterised for their functional association with IGF-I. For example,
TG2 has been found to form direct complexes with β1, β3 and β5
integrin subunits as well as bind to consensus sequences present in 13
of the 18 human α integrins [reviewed in 30]. Similarly, ECM proteins
such as VN and FN are well-established substrates of TGases and are
known to closely associate with IGF-I, highlighting a plausible involve-
ment of TGases in IGF-I signalling axis.
4.2. The D-domain lysine residues are functionally signiﬁcant
TheD-domain of IGF-I has occasionally been characterised for its bind-
ing afﬁnity for receptors, IGF-1R and the type-2 IGF receptor (IGF-IIR), but
its functional role has never been elucidated. A study showed that the de-
letion of the IGF-ID-domainhad anegligible effect on IGF-1Rbinding [11].
However, this ﬁnding was in contrast to another study wherein thesubstitution of the charged residues in the IGF-I D-domain, K65 and K68
to alanine, demonstrated a 10-fold decrease in IGF-1R afﬁnity [53]. Fur-
thermore, a recent IGF-I PEGylation study found that unPEGylated R27/
R65-IGF-I did not affect IGF-1R binding afﬁnity [54]. However, the contri-
bution of the D-domain to IGF-1R binding afﬁnity appears different for
IGF-II when compared to IGF-I.When the D-domain of IGF-I was replaced
with the IGF-II D-domain there was little effect on IGF-1R binding but a
2.6-fold increase in IGF-1R binding was observed when IGF-II contained
the IGF-I D-domain [53]. Hence, the role of IGF-I D-domain continues to
be a mystery and deﬁnitely warrants further investigations.
Functions of IGF-I have been shown to be modulated through its in-
teractions with IGFBPs and other proteins present in the ECM [55]. This
has led to the concept that ECM-bound IGFBPs may serve as reservoirs
of IGF-I within tissues, concentrating IGFs in close proximity to the
IGF-1R to facilitate increased receptor activation [56–59]. Indeed, stud-
ies from our laboratory have shown that IGF-I binds effectively to VN
through IGFBP-3 and such IGF-I:IGFBP:VN complex formation enhances
downstreambiological functions through simultaneously engaging IGF-
1R and VN-binding integrins [41]. In view of this, we investigated the
effects of single K→R substitutions in IGF-I when incorporated into
complexes with IGFBP-3 and VN. To ensure that any observed effects
were not simply due to a changed afﬁnity between the analogues and
IGFBP-3, we ﬁrst assessed the kinetics of the K→R IGF-I:IGFBP-3 via
SPR. The kinetic constants and resultant KD values for all analogues
showed less than twofold change compared to wtIGF-I values and in
good agreement with previously observed literature values [49,60],
wherein afﬁnity of rIGF-I to IGFBP-3 was observed to be of the order
10−10 M KD. This is not surprising since the single conservative substi-
tution of K→R renders no signiﬁcant changes to its charge distribution
or to the bulk of the molecule, minimising effects on the tertiary struc-
ture of IGF-I and its subsequent binding to IGFBP-3. Moreover, previous
deletion/mutation studies of IGF-I have shown residues 8–18 and 49–51
of IGF-I to be important for IGFBP-3 binding [61], which remain distinct
from the three lysine residues investigated. Similarly, previous studies
have shown that IGF-I C-domain confers no effect on IGFBP binding
[11,62,63]. More so, removal of the D-domain has demonstrated a four-
fold increase in its serum IGFBP binding afﬁnity [11]. Taken together,
these studies suggest that all the three lysine residues of interest show
no association with IGFBPs which is further validated in existing IGF-I:
IGFBP crystal structures [6].
The functional implications of these lysine-substituted IGF-I amino
acid residues were tested in assays using MCF-7 breast cancer cells. On
several occasions we have reported the use of substrate-bound VN as a
means to capture IGFBPs bound to IGF-I, and in turn more closely
mimic the in vivo environment wherein cells in tissues are exposed to
ECM-bound IGF-I. Indeed, there is emerging evidence to support that
the cellular responses of IGF-I can be mediated by its association with
the proteins present in theECM that function to stabilise IGF-I concentra-
tions within the matrix and thereby, promote receptor interactions
[55,59]. Hence, the substrate-bound approach was employed to investi-
gate cell viability andmigration as well as activation of downstream sig-
nalling pathways in the presence of VN, IGFBP-3 and the K→R IGF-I
analogues. Our results indicate that cell viability remained unaffected
for all the IGF-Is tested (native and K→R). Maintenance of MCF-7 cell
viability is believed to be induced predominantly by the ERK/MAPK
pathway [64]. This aligns with our ERK/MAPK activation data that dem-
onstrates consistent activation of ERK1/2 between native and IGF-I ana-
logues. This may be due to the activation of integrins expressed onMCF-
7 cells (αvβ1, αvβ3, αvβ5) by the VN present in the assay conditions.
Particularly, ligand occupancy of the VN-binding αvβ3 integrin has pre-
viously been shown to affect downstream signalling mediated by MAPK
[65]. Interestingly, in our study VN alone appears to stimulate ERK1/2
phosphorylation at earlier time points. Such short term transiently in-
duced ERK1/2 phosphorylation has been previously reported by our
group and is reasoned to be due to a short burst in VN-mediated, com-
plex independent activation of ERK [44]. Nevertheless, changes in
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the treatments including IGF-I analogues, which is further supported
by our cell viability data. The interactions of RTKs such as PDGFR,
VEGFR and EGFR with integrins have also been shown to induce a tran-
sient activation of ERK [66]. IGF-1R being a part of the same RTK receptor
family, it may be possible that a similar mechanism may be involved in
the activation of MAPK/ERK pathway. Nevertheless, future studies will
be directed at using inhibitors (chemical or blocking antibody) directed
against ERK1/2 as well as integrins to assess their relative contributions
to the observed cell viability effects.
In contrast to the effects observed with cell viability, cell migration
stimulated by R27-IGF-I was comparable to wtIGF-I, whereas both
R65- and R68-IGF-I analogues were unable to stimulate cell migration
above the VN-only control. When downstream signalling pathways im-
plicated in cell migration were investigated, it was observed that the
R65- and R68-IGF-I analogues were not capable of stimulating IGF-1R
phosphorylation and showed a concomitant reduction in the phosphor-
ylated levels of AKT. This is consistentwith the data from previous stud-
ies using chemical inhibitors, U0126 against the ERK/MAPK pathway
and LY294002 against the PI3-K/AKT pathway, that demonstrate
migration induced by the IGF-I:IGFBP:VN heterotrimeric complexes is
predominantlymediated through the PI3-K/AKTpathway,with little in-
volvement of the ERK/MAPK pathway [41]. In addition, other studies
have demonstrated the importance of the PI3-K/AKT pathway in IGF-
I-dependent motility in ﬁbroblasts and tumour cells [67–69], in which
AKT, through interactions with proteins such as Rac and Cdc42,
has been shown to modulate actin organisation and microtubule
stabilisation. Additionally, Romanelli et al. demonstrated that the
sustained AKT as well as IGF-1R phosphorylation was reduced when
IGF-1R internalisation and recycling were blocked, indicating a possible
association between the IGF-1R internalisation process and IGF-1R/AKT
phosphorylation [70,71]. Follow-up approaches to characterise IGF-1R
binding kinetics as well as studying the extent of involvement of signal-
ling pathways such as the PI3-K/AKT pathway will be of great help to
further investigate the mechanisms of K→R IGF-I analogues.
In summary, thismanuscript introduces the potential functional sig-
niﬁcance of the lysine residues in the D-domain of IGF-I. Furthermore,
considering that TGases are increasingly being implicated in RTK signal-
ling, this study opens up the possibility for TGases having a role in me-
diating IGF-I signalling, possibly through the immobilisation of IGF-I to
the proteins present in the ECMvia its D-domain. Indeed, novel ﬁndings
reported in this manuscript provide exciting new evidences in the
ﬁeld of IGF-I research that can be built upon to elucidate additional
uncharacterised and biologically relevant molecular mechanisms
governing the IGF axis.Acknowledgements
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